Center-Authored Papers

Filters: Author is Kantarjian, Hagop  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yeh C-H, Tseng R, Hannah A, Estrov Z, Estey E, Kantarjian H, Albitar M.  2010.  Clinical correlation of circulating heat shock protein 70 in acute leukemia.. Leukemia research. 34(5):605-9. Abstract
Yanada M, Borthakur G, Garcia-Manero G, Ravandi F, Faderl S, Pierce S, Kantarjian H, Estey E.  2008.  Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia.. Leukemia research. 32(10):1505-9. Abstract
Yanada M, Borthakur G, Ravandi F, Bueso-Ramos C, Kantarjian H, Estey E.  2008.  Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia.. Haematologica. 93(8):1263-5.
Yanada M, Garcia-Manero G, Borthakur G, Ravandi F, Kantarjian H, Estey E.  2008.  Relapse and death during first remission in acute myeloid leukemia.. Haematologica. 93(4):633-4.
T
Tsimberidou AM, Keating MJ, Jabbour EJ, Ravandi-Kashani F, O'Brien S, Estey E, Bekele N, Plunkett WK, Kantarjian H, Borthakur G.  2014.  A Phase I Study of Fludarabine, Cytarabine, and Oxaliplatin Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia.. Clinical lymphoma, myeloma & leukemia. 14(5):395-400.e1. Abstract
Tsimberidou AM, Estey E, Wen S, Pierce S, Kantarjian H, Albitar M, Kurzrock R.  2008.  The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.. Cancer. 113(7):1605-13. Abstract
Tefferi A, Kantarjian H, Rajkumar VS, Baker LH, Abkowitz JL, Adamson JW, Advani RH, Allison J, Antman KH, Bast RC et al..  2015.  In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.. Mayo Clinic proceedings.
S
Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S et al..  2010.  DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(4):605-13. Abstract
Schanz J, Steidl C, Fonatsch C, Pfeilstöcker M, Nösslinger T, Tuechler H, Valent P, Hildebrandt B, Giagounidis A, Aul C et al..  2011.  Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(15):1963-70. Abstract
R
Ravandi F, Estey E, Jones D, Faderl S, O'Brien S, Fiorentino J, Pierce S, Blamble D, Estrov Z, Wierda W et al..  2009.  Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(4):504-10. Abstract
N
Nazha A, Bueso-Ramos C, Estey E, Faderl S, O'Brien S, Fernandez MH, Nguyen M, Koller C, Freireich E, Beran M et al..  2013.  The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia.. Frontiers in oncology. 3:218. Abstract
K
Konopleva M, Thall PF, Arana Yi C, Borthakur G, Coveler A, Bueso-Ramos C, Benito J, Konoplev S, Gu Y, Ravandi F et al..  2015.  Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.. Haematologica. Abstract
Kantarjian H, Fenaux P, Sekeres MA, Becker PS, Boruchov A, Bowen D, Hellstrom-Lindberg E, Larson RA, Lyons RM, Muus P et al..  2010.  Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(3):437-44. Abstract
Kantarjian H, Wilson W, Ravandi F, Estey E.  2013.  Decitabine in older adults with acute myeloid leukemia: why was the dream broken? Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(14):1795-6.
Kantarjian H, Cortes J, Kim D-W, Dorlhiac-Llacer P, Pasquini R, DiPersio J, Müller MC, Radich JP, Khoury JH, Khoroshko N et al..  2009.  Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.. Blood. 113(25):6322-9. Abstract
H
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S et al..  2017.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.. The New England journal of medicine. 376(10):917-927. Abstract
G
Garcia-Manero G, Fenaux P, Al-Kali A, Baer MR, Sekeres MA, Roboz GJ, Gaidano G, Scott BL, Greenberg P, Platzbecker U et al..  2016.  Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.. The Lancet. Oncology. Abstract
F
Fenaux P, Muus P, Kantarjian H, Lyons RM, Larson RA, Sekeres MA, Becker PS, Orejudos A, Franklin J.  2017.  Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy.. British journal of haematology. Abstract
C
le Coutre P, Ottmann OG, Giles F, Kim D-W, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG et al..  2008.  Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.. Blood. 111(4):1834-9. Abstract
B
Borthakur G, Cortes JE, Estey EE, Jabbour E, Faderl S, O'Brien S, Garcia-Manero G, Kadia TM, Wang X, Patel K et al..  2014.  Gemtuzumab Ozogamicin with Fludarabine, Cytarabine and Granulocyte Colony Stimulating Factor (FLAG-GO) As Front-line Regimen in Patients with Core Binding Factor Acute Myelogenous Leukemia.. American journal of hematology. 89(10):964-8. Abstract
Borthakur G, Kantarjian H, Wang X, Plunkett WK, Gandhi VV, Faderl S, Garcia-Manero G, Ravandi F, Pierce S, Estey EH.  2008.  Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival.. Cancer. 113(11):3181-5. Abstract
Borthakur G, Popplewell L, Boyiadzis M, Foran J, Platzbecker U, Vey N, Walter RB, Olin R, Raza A, Giagounidis A et al..  2016.  Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies.. Cancer. 122(12):1871-9. Abstract
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F et al..  2009.  Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 27(35):6041-51. Abstract
A
Armistead PM, DeLima M, Pierce S, Qiao W, Wang X, Thall PF, Giralt S, Ravandi F, Kantarjian H, Champlin R et al..  2009.  Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(11):1431-8. Abstract
Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E, Faderl S, O'Brien S, Wierda W, Pierce S et al..  2017.  Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab.. Blood. 129(10):1275-1283. Abstract